Efficacy

Efficacy of Ilumya (Tildrakizumab) for Psoriasis

Ilumya (tildrakizumab) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Tildrakizumab is a monoclonal antibody that targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes and implicated in the pathogenesis of psoriasis. Clinical trials have demonstrated that Ilumya can lead to significant skin clearance in many patients. In pivotal Phase III trials, such as reSURFACE 1 and reSURFACE 2, a substantial proportion of patients treated with Ilumya achieved at least a 75% reduction in Psoriasis Area and Severity Index (PASI 75) scores, which is a common measure of psoriasis severity.

The efficacy of Ilumya in clinical settings has been further supported by long-term studies, showing that the improvements in psoriasis symptoms can be maintained with continued use. The safety and efficacy profile of Ilumya, as evidenced by these studies, has made it a valuable treatment option for individuals suffering from chronic plaque psoriasis, with some patients achieving nearly complete skin clearance over time.

Efficacy of Wezlana (Ustekinumab-auub) for Psoriasis

Wezlana (ustekinumab-auub) is a biosimilar to the original biologic drug ustekinumab, which is marketed under the brand name Stelara. Ustekinumab, including its biosimilar Wezlana, is also approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy. Ustekinumab is a monoclonal antibody that targets the p40 subunit of interleukins IL-12 and IL-23, which are key mediators in the inflammatory process of psoriasis. Clinical trials have shown that ustekinumab can lead to significant improvement in psoriasis symptoms, with many patients achieving PASI 75 responses and even higher levels of skin clearance (PASI 90 or PASI 100).

As a biosimilar, Wezlana has been shown to have no clinically meaningful differences in terms of safety, purity, and potency when compared to its reference product, Stelara. This means that patients can expect similar efficacy in the treatment of plaque psoriasis with Wezlana as they would with the original biologic, ustekinumab. The introduction of biosimilars like Wezlana provides more treatment options for patients and may offer cost benefits while maintaining high efficacy in managing psoriasis symptoms.